CCNA2 and neoplasm: Histopathological analyses of the tumour mass demonstrated the ability of BRB and, to a lesser extent of EA, to inhibit tumour cell proliferation and progression, and to reduce mRNA levels of pro-inflammatory (Cxcl1, Mif, and Nfe2l2), antiapoptotic and cell cycle associated biomarkers (Birc5, Aurka, Ccna1, Ccna2) [116].